Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Central Univ. of Punjab EGFR compound 4i: sourced facts only. name: "The EGFR inhibitory activity of these compounds was then assessed, and 4h (IC50 = 86.9 nM) and 4i (IC50 = 154.35 nM) exhibited greater activity than erlotinib (IC50 = 197.94 nM)." [PMID:42339275]; target: "The EGFR inhibitory activity of these compounds was then assessed, and 4h (IC50 = 86.9 nM) and 4i (IC50 = 154.35 nM) exhibited greater activity than erlotinib (IC50 = 197.94 nM)." [PMID:42339275]; developer: "Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Health Sciences, Central University of Punjab Bathinda 151401 India [email protected] [email protected]." [PMID:42339275]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Central Univ. of Punjab EGFR compound 4i.